Current management of JIA is, similarly to RA, based on introduction of varying regimens based on administration of anti-inflammatory drugs including methotrexate, glucocorticoid and anti-TNF-alpha monoclonal antibodies. This evidence concerns the gene TNF and juvenile idiopathic arthritis.